四跨膜蛋白在胃癌中的表达和意义

国际肿瘤学杂志››2017,Vol. 44››Issue (7): 537-540.doi:10.3760/cma.j.issn.1673-422X.2017.07.015

四跨膜蛋白在胃癌中的表达和意义

聂晓飞，邱振康，刘宁，齐卫卫，丁爱萍，邱文生

266071 青岛大学附属医院肿瘤科

收稿日期:2016-12-05出版日期:2017-07-08发布日期:2017-06-20
通讯作者:邱文生 E-mail:wsqiuqd@163.com
基金资助:

国家自然科学基金（81472338）

Expression and significance of tetraspanin in gastric cancer

Nie Xiaofei, Qiu Zhenkang, Liu Ning, Qi Weiwei, Ding Aiping, Qiu Wensheng

Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266071, China

Received:2016-12-05Online:2017-07-08Published:2017-06-20
Contact:Qiu Wensheng E-mail:wsqiuqd@163.com
Supported by:

National Natural Science Foundation of China (81472338)

摘要/Abstract

摘要：四跨膜蛋白是一类表达非常广泛的细胞表面糖蛋白，可以与整合素、信号蛋白、生长因子等多种细胞表面分子结合并发挥功能。近年来越来越多的研究提示四跨膜蛋白与恶性肿瘤的侵袭、转移密切相关，并且显示出一定的临床价值，可作为恶性肿瘤诊断和预后的新指标。

聂晓飞，邱振康，刘宁，齐卫卫，丁爱萍，邱文生. 四跨膜蛋白在胃癌中的表达和意义[J]. 国际肿瘤学杂志, 2017, 44(7): 537-540.

Nie Xiaofei, Qiu Zhenkang, Liu Ning, Qi Weiwei, Ding Aiping, Qiu Wensheng. Expression and significance of tetraspanin in gastric cancer[J]. Journal of International Oncology, 2017, 44(7): 537-540.

［1］ Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance［J］. J Cell Sci, 2014, 127(Pt 17): 3641-3648. DOI: 10.1242/jcs.154906. ［2］ Shiwu WU, Lan Y, Wenqing S, et al. Expression and clinical significance of CD82/KAI1 and Ecadherin in nonsmall cell lung cancer［J］. Arch Iran Med, 2012, 15(11): 707-712. DOI: 0121511/AIM.0012. ［3］ Zhang W, Zhao CG, Sun HY, et al. Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma［J］. Gut Liver, 2014, 8(5): 536-542. DOI: 10.5009/gnl13331. ［4］ Knoener M, Krech T, Puls F, et al. Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer［J］. Dis Markers, 2012, 32(6): 337-342. DOI: 10.3233/DMA-2012-0896. ［5］周蕾, 武世伍, 俞岚, 等. 胃腺癌组织KAI1的表达及与血管、淋巴管生成的关系［J］. 四川大学学报: 医学版, 2014, 45(1): 43-48. DOI: 10.13464/j.scuxbyxb.2014.01.010. ［6］ Zheng HC, Wang MC, Li JY, et al. Expression of maspin and kai1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer［J］. Chin Med Sci J, 2004, 19(3): 193-198. ［7］ Huan J, Gao Y, Xu J, et al. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma［J］. Int J Clin Exp Pathol, 2015, 8(3): 3054-3061. ［8］ Kischel P, Bellahcene A, Deux B, et al. Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases［J］. Anticancer Res, 2012, 32(12): 5211-5220. ［9］ Chen Z, Gu S, Trojanowicz B, et al. Downregulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma［J］. World J Surg Oncol, 2011, 9: 43. DOI: 10.1186/1477-7819-9-43. ［10］张徐宁, 季润元, 史恩溢, 等. 胃癌组织中MRP1/CD9、KAI1/CD82和ME491/CD63的表达及意义［J］. 广东医学, 2013, 34(21): 3264-3266. ［11］ Hori H, Yano S, Koufuji K, et al. CD9 expression in gastric cancer and its significance［J］. J Surg Res, 2004, 117(2): 208-215. DOI: 10.1016/j.jss.2004.01.014. ［12］ Soyuer S, Soyuer I, Unal D, et al. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy［J］. Pathol Res Pract, 2010, 206(9): 607-610. DOI: 10.1016/j.prp.2010.04.004. ［13］ Murayama Y, Oritani K, Tsutsui S. Novel CD9targeted therapies in gastric cancer［J］. World J Gastroenterol, 2015, 21(11): 3206-3213. DOI: 10.3748/wjg.v21.i11.3206. ［14］ Qin Y, Mohandessi S, Gordon L. Regulation of FAK activity by tetraspan proteins: potential clinical implications in cancer［J］. Crit Rev Oncog, 2015, 20(5-6): 391-405. DOI: 10.1615/CritRevOncog.v20.i5-6.110. ［15］ Schenk GJ, Dijkstra S, van het Hof AJ, et al. Roles for HBEGF and CD9 in multiple sclerosis［J］. Glia, 2013, 61(11): 1890-1905. DOI: 10.1002/glia.22565. ［16］ Wang HX, Hemler ME. Novel impact of EWI2, CD9, and CD81 on TGFβ signaling in melanoma［J］. Mol Cell Oncol, 2015, 2(1): e1030536. DOI: 10.1080/23723556.2015.1030536. ［17］ Kwon MJ, Seo J, Kim YJ, et al. Prognostic significance of CD151 overexpression innonsmall cell lung cancer［J］. Lung Cancer, 2013, 81(1): 109-116. DOI: 10.1016/j.lungcan.2013.03.014. ［18］ Suzuki S, Miyazaki T, Tanaka N, et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness［J］. Ann Surg Oncol, 2011, 18(3): 888-893. DOI: 10.1245/s10434-010-1387-3. ［19］ Kwon MJ, Park S, Choi JY, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer［J］. Br J Cancer, 2012, 106(5): 923-930. DOI: 10.1038/bjc.2012.11. ［20］ Yang YM, Zhang ZW, Liu QM, et al. Overexpression of CD151 predicts prognosis in patients with resected gastric cancer［J］. PLoS One, 2013, 8(3): e58990. DOI: 10.1371/journal.pone.0058990. ［21］ Kang BW, Lee D, Chung HY, et al. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer［J］. J Cancer Res Clin Oncol, 2013, 139(11): 1835-1843. DOI: 10.1007/s00432-013-1503-4. ［22］ Ha SY, Do IG, Lee J, et al. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer［J］. Ann Surg Oncol, 2014, 21(4): 1099-1106. DOI: 10.1245/s10434013-3339-1. ［23］ Zhu H, Wu Y, Zheng W, et al. CO029 is overexpressed in gastric cancer and mediates the effects of EGF on gastric cancer cell proliferation and invasion［J］. Int J Mol Med, 2015, 35(3): 798802. DOI: 10.3892/ijmm.2015.2069. ［24］ Wei L, Li Y, Suo Z. TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway［J］. Int J Clin Exp Med, 2015, 8(6): 8599-8607. ［25］ Anami K, Oue N, Noguchi T, et al. TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer［J］. Gastric Cancer, 2016, 19(2): 370-380. DOI: 10.1007/s10120-015-0478-z. ［26］ Chen L, Li X, Wang GL, et al. Clinicopathological significance of overexpression of TSPAN1, KI67 and CD34 in gastric carcinoma［J］. Tumori, 2008, 94(4): 531-538. ［27］ Lu Z, Luo T, Nie M, et al. TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR573［J］. FEBS Lett, 2015, 589(15): 1988-1994. DOI: 10.1016/j.febslet.2015.05.044. ［28］ He P, Wang S, Zhang X, et al. Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer［J］. Oncotarget, 2016, 7(26): 40160-40173. DOI: 10.18632/oncotarget.9514. ［29］ Yoo TH, Ryu BK, Lee MG, et al. CD81 is a candidate tumor suppressor gene in human gastric cancer［J］. Cell Oncol, 2013, 36(2): 141-153. DOI: 10.1007/s13402-012-0119-z.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	解淑萍, 孙亚红, 汪超.早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[11]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[12]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[13]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[14]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[15]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.